Melatonin treatment for tardive dyskinesia: A double-blind, placebo-controlled, crossover study

Archives of General Psychiatry

Volumn 58, Issue 11, 2001, Pages 1049-1052

  Shamir, Eyal ^a,b   Barak, Yoram ^a,b   Shalman, Irena ^a,b   Laudon, Moshe ^b   Zisapel, Nava ^b   Tarrasch, Ricardo ^b   Elizur, Avner ^a,b   Weizman, Ronit ^b,c  

^a ABARBANEL MENTAL HEALTH CENTER   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

^c SHALVATA MENTAL HEALTH CENTER   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

CIRCADIAN; DOPAMINE RECEPTOR; MELATONIN;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORPUS STRIATUM; CROSSOVER PROCEDURE; DOPAMINE RELEASE; DOPAMINERGIC ACTIVITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG POTENCY; FEMALE; HUMAN; HYPOTHALAMUS; MALE; NEUROTOXICITY; NIGRONEOSTRIATAL SYSTEM; OXIDATIVE STRESS; RANDOMIZED CONTROLLED TRIAL; SCHIZOPHRENIA; TARDIVE DYSKINESIA;

EID: 0035158194     PISSN: 0003990X     EISSN: None     Source Type: Journal    
DOI: 10.1001/archpsyc.58.11.1049     Document Type: Article

References (30)

1. Integrating incidence and prevalence of tardive dyskinesia
2. Identifying risk factors for tardive dyskinesia among long-term outpatients maintained with neuroleptic medications: Results of the Yale Tardive Dyskinesia Study
3. Predicting the long-term risk of tardive dyskinesia in outpatients maintained on neuroleptic medications
4. Dystonia and dyskinesia
5. Randomised double-blind comparison of the incidence of tardive dyskinesia in patients with schizophrenia during long-term treatment with olanzapine or haloperidol
6. Vitamin E (alpha-tocopherol) in the treatment of tardive dyskinesia: A statistical meta-analysis
7. Branched chain amino acids decrease tardive dyskinesia symptoms
8. Progress in the treatment of tardive dyskinesia: Theory and practice
9. Vitamin E treatment for tardive dyskinesia
10. The oxidant/antioxidant network: Role of melatonin
11. Serum amino acids, central monoamines, and hormones in drug-naive, drug-free, and neuroleptic-treated schizophrenic patients and healthy subjects
12. Melatonin protects 6-OHDA-induced neuronal death of nigrostriatal dopaminergic system
13. Inhibition of dopamine release by melatonin: Regional distribution in the rat brain
14. The use of melatonin for sleep
15. Assessment of tardive dyskinesia using the Abnormal Involuntary Movement Scale
16. Alpha-tocopherol in tardive dyskinesia
17. Treatment of tardive dyskinesia with vitamin E
18. Vitamin E in the treatment of tardive dyskinesia: A double-blind placebo-controlled study
19. Vitamin E treatment of tardive dyskinesia
20. Effectiveness of vitamin E for treatment of long-term tardive dyskinesia
21. Vitamin E in the treatment of tardive dyskinesia: A replication study
22. Long-term treatment effects of vitamin E for tardive dyskinesia
23. Induction of NF-κB activity during haloperidol-induced oxidative toxicity in clonal hippocampal cells: Suppression of NF-κB and neuroprotection by antioxidants
24. Depletion of glutathione and enhanced lipid peroxidation in the CSF of acute psychotics following haloperidol administration
25. Enhanced glial cell line-derived neurotrophic factor mRNA expression upon (-)-deprenyl and melatonin treatments
26. Melatonin and the seasonal control of reproduction
27. Melatonin-dopamine interaction in the striatal projection area of sensorimotor cortex in the rat
28. Melatonin administration increases the affinity of D2 dopamine receptors in the rat striatum
29. Orphan neurones and amine excess: The functional neuropathology of Parkinsonism and neuropsychiatric disease
30. Is melatonin treatment effective for tardive dyskinesia?